RCS - IXICO plc - HD-IH Consortium

IXICOAnnouncement

21/09/2022 10:45

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220921:nRSU1514Aa&default-theme=true

RNS Number : 1514A  IXICO plc  21 September 2022

21September 2022

IXICO plc

("IXICO" or the "Company")

 

HD-IH Consortium

 

IXICO plc (AIM: IXI), the medical imaging advanced analytics company
delivering intelligent insights in neuroscience, today provides further
information on the HD-IH consortium it announced in its RNS dated 10(th) May
2022.  This information is being released on various platforms including the
Company's website.

 

Call to Action - New consortium will use artificial intelligence technology to
conduct large-scale analysis of brain changes in Huntington's disease

New York, NY / London, UK, September 21 2022; IXICO, uniQure, PTC
Therapeutics, Inc, and CHDI Foundation have formed the Huntington's Disease
Imaging Harmonization Consortium (HD-IH) to better understand the structural
brain changes that occur over the course of HD. Accurate segmentation of
magnetic resonance images (MRIs) is essential to measuring the brain's
anatomical structures, and the HD-IH consortium will establish a data
repository to enable pharmaceutical and nonprofit members to develop more
targeted therapeutic strategies, inform eligibility and dosing decisions, and
aid associated trial design and biomarker development.

The HD-IH consortium aims to analyse more than 6,000 participant-visit MRIs
that were acquired from over 2,000 participants enrolled in the TRACK-HD,
PREDICT-HD, and IMAGE-HD natural history studies. A first of its kind, the
plan is to systematically conduct harmonized analysis across all three study
cohorts to produce a rich dataset that will give insight into key brain
volumetric biomarkers over the course of HD. Using IXICO's artificial
intelligence-based IXIQ.Ai analysis platform, HD-IH will build a high-quality
data repository using both fully automated segmentation techniques and manual
correction steps during quality control to provide more precise volumetric
data for analyses.

"The imaging harmonization that this consortium is conducting will be a
turning point in the development of volumetric MRI biomarkers to monitor
disease progression and response to interventions in Huntington's disease,"
said Cristina Sampaio, Chief Medical Officer at CHDI. "Groundwork of this sort
is foundational for scientific breakthroughs."

 

In its current phase, scheduled to be completed by the end of 2022, the
consortium's founding members are setting up the data analytics infrastructure
and completing the analysis of approximately one third of the images.

 

High quality caudate and putamen volumetric data were recently chosen as
landmark variables for entry into Stage 1 of the new Huntington's Disease
Integrated Staging System (HD-ISS), when demonstrable neurodegeneration can be
detected by changes in these biomarkers. Consequently, the HD-IH consortium
members are working together with clinical and scientific HD experts to
translate Stage 1 cut-off tables so that the HD-ISS criteria can be readily
applied within this imaging analysis platform, thereby enabling robust
implementation of the HD-ISS in future clinical trials.

 

IXICO's Marina Papoutsi presented the aims of the consortium at the recent
European Huntington's Disease Network (EHDN) Imaging Working Group meeting on
September 15, 2022, which was part of the EHDN Plenary Meeting in Bologna,
Italy. Presentation slides can be accessed online: https://bit.ly/3S20l4e
(https://gbr01.safelinks.protection.outlook.com/?url=https%3A%2F%2Fbit.ly%2F3S20l4e&data=05%7C01%7Crobin.wolz%40ixico.com%7C415a68954bc54b03131b08da9b0aded9%7Cd5a3b5c97a6b4ab9abee3de97e9d4955%7C0%7C0%7C637992768245796961%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000%7C%7C%7C&sdata=sP4gx6qXYUiIqPVHGuxKCFPEpXUfoxj15GGfXlbqoY8%3D&reserved=0)

 

Founding members of the HD-IH consortium are inviting additional members to
join and contribute to the ongoing image analysis of the remaining data. New
members will have full access to all participant-visit results performed to
date and will define priorities for upcoming activities to enable targeted
planning for their upcoming HD research and clinical trials. Following an
exclusivity period, the consortium is committed to making the full dataset
available to the wider scientific community.

Robin Wolz, Chief Scientific Officer at IXICO, commented, "Harmonized analysis
across heterogeneous data is a critical requirement to enable more targeted
clinical trial design through the inclusion of novel biomarkers. We're excited
to support this important project in our endeavour to bring novel imaging
biomarkers into clinical trials."

 

 

 

For further information please contact:

 

 IXICO plc
 Giulio Cerroni, Chief Executive Officer           +44 (0)20 3763 7499

 Grant Nash, Chief Financial Officer

 Cenkos Securities PLC (Nominated adviser and sole broker)                         +44 (0)20 7397 8900
 Giles Balleny / Max Gould (Corporate Finance)
 Michael F Johnson / Tamar Cranford-Smith (Sales)

About IXICO | Advanced Analytics | Intelligent Insights.

IXICO is dedicated to delivering insights in neuroscience to help transform
the advancement of investigational therapies for neurological diseases, such
as Huntington's disease, Parkinson's disease and Alzheimer's disease. The
Company's purpose is to advance medicine and human health by turning data into
clinically meaningful information, providing valuable new insights in
neuroscience by supporting pharmaceutical companies across all phases of CNS
clinical research. IXICO's goal is to be a leading advocate of artificial
intelligence in medical image analysis.

 

IXICO has developed and deployed breakthrough data analytics, at scale,
through its remote access technology platform, to improve the return on
investment in drug development and reduce risk and uncertainty in clinical
trials for the Company's pharmaceutical clients.

 

More information is available on www.IXICO.com (http://www.IXICO.com)

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAKFLBLLKLXBBX